Compare Invesco Ltd. (IVZ) vs Oscar Health Inc (OSCR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco Ltd. vs Oscar Health Inc — how do they compare? Invesco Ltd. trades at $29.68 (market cap $13.15B), while Oscar Health Inc trades at $29.73 (market cap $8.92B). The key difference: Invesco Ltd. is the larger of the two by market cap, and Invesco Ltd. pays a 2.9% dividend while Oscar Health Inc pays none. Which is the better fit depends on your goals.
| IVZ | OSCR | |
|---|---|---|
Market Cap | $13.15B | $8.92B |
Sector | Financials | Health |
52-Week High | $30.30 | $32.18 |
52-Week Low | $20.20 | $10.85 |
Enterprise Value | $23.39B | $4.55B |
Dividend Yield | 2.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Invesco (IVZ) trades at $29.57, down 0.2% on the day, with a bullish technical outlook supported by moving averages despite overbought RSI readings. The company reported revenue growth to $6.38B in 2025 but posted a net loss of -$281.70M, reflecting margin pressures. Recent earnings show mixed results, beating estimates in Q3 and Q4 2025 but missing in Q1 2026. Positive cash flow from operations of $1.53B in 2025 highlights operational strength, while analyst sentiment leans neutral with a consensus price target of $30.64.
The stock presents a cautious opportunity with solid revenue growth and improving cash flows offset by profitability challenges. Near-term catalysts include potential earnings recovery and dividend payments, but risks from competitive pressures and macroeconomic volatility warrant careful monitoring. The current price near the consensus target suggests limited upside without fundamental improvements.
Oscar Health (OSCR) trades at $29.60, up 1.72% today, showing mixed signals with a bullish technical trend but bearish oscillators. The company reported revenue growth to $11.70B in 2025, though net income remains negative at -$443.15M. Recent earnings beat expectations in Q1 2026 with EPS of $2.07, while analyst sentiment is divided with a consensus price target of $24.67. Positive cash flow trends and media coverage highlight growth potential amid ongoing profitability challenges.
Outlook: OSCR offers growth exposure in health insurance with strong revenue expansion and cash flow, but profitability risks persist. Investment opportunity lies in execution toward breakeven, while risks include margin pressure and competitive threats. The stock's current price above consensus target suggests cautious optimism is warranted.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →About Oscar Health Inc
Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →
